Clinical Trial

A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab as firstline treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-06-03; most recent amendment 2026-05-05.
Status change: Recruiting → Active, Not Recruiting 2026-03-11
Trial Details
NCT Number NCT06448312
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 406 participants
Start Date 2024-06-07
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-08